Barclays analyst Matthew Bouley maintains Core & Main (NYSE:CNM) with a Overweight and lowers the price target from $29 to $28.
Nautilus Biotechnology Q3 EPS $(0.11) Beats $(0.15) Estimate
Nautilus Biotechnology (NASDAQ:NAUT) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.15) by 26.67 percent. This is a 8.33 percent increase over losses of $(0.12) per share
